Acquisition by Stewart Strong of 6313 shares of Haemonetics at 95.73 subject to Rule 16b-3
| HAE Stock | USD 76.30 1.53 2.05% |
About 55% of Haemonetics' shareholders are presently thinking to get in. The analysis of overall sentiment of trading Haemonetics stock suggests that some investors are interested at this time. The current market sentiment, together with Haemonetics' historical and current headlines, can help investors time the market. In addition, many technical investors use Haemonetics stock news signals to limit their universe of possible portfolio assets.
Haemonetics | Build AI portfolio with Haemonetics Stock |
Filed transaction by Haemonetics Officer President, Global Hospital. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Haemonetics Fundamental Analysis
We analyze Haemonetics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Haemonetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Haemonetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Haemonetics is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Haemonetics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Haemonetics stock to make a market-neutral strategy. Peer analysis of Haemonetics could also be used in its relative valuation, which is a method of valuing Haemonetics by comparing valuation metrics with similar companies.
Peers
Haemonetics Related Equities
| CNMD | CONMED | 2.28 | ||||
| ICUI | ICU Medical | 2.09 | ||||
| IART | Integra LifeSciences | 2.03 | ||||
| ANGO | AngioDynamics | 1.29 | ||||
| COO | Cooper Companies, | 0.82 | ||||
| MMSI | Merit Medical | 0.81 | ||||
| ATR | AptarGroup | 1.57 |
Complementary Tools for Haemonetics Stock analysis
When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |